By Fineline Cube Adcentrx Therapeutics announced today that China’s National Medical Products Administration (NMPA) has cleared the company’s Investigational New Drug (IND) application for ADRX-0405, enabling inclusion of China-based clinical centers in its ongoing Phase 1a/1b trial (NCT06710379) evaluating the potential first-in-class antibody-drug conjugate (ADC) in patients with late-stage solid tumors.
Regulatory Milestone
| Component | Detail |
|---|---|
| Drug Candidate | ADRX-0405 |
| Developer | Adcentrx Therapeutics |
| Regulatory Authority | National Medical Products Administration (NMPA), China |
| Approval Type | IND clearance |
| Target Indications | Metastatic castration-resistant prostate cancer, gastric cancer, and non-small cell lung cancer |
| Trial Identifier | NCT06710379 (Phase 1a/1b) |
Drug Profile & Mechanism
STEAP1-Targeting Innovation
- Target: Six-transmembrane epithelial antigen of the prostate 1 (STEAP1)
- Expression Profile: Overexpressed in prostate cancer and certain other solid tumors with limited expression in healthy tissue
- Therapeutic Class: Potential first-in-class, next-generation antibody-drug conjugate (ADC)
- Differentiation: Novel target with favorable tumor-to-normal tissue selectivity ratio
Clinical Development Plan
Phase 1a/1b Trial Design
| Parameter | Detail |
|---|---|
| Study Type | Open-label, multicenter, dose escalation and expansion |
| Patient Population | Select advanced solid tumors including mCRPC, gastric cancer, and NSCLC |
| Primary Objectives | Safety/tolerability assessment and optimal dose determination |
| Geographic Expansion | Addition of China-based clinical centers following NMPA clearance |
| Timeline | Phase 1a completion anticipated Q4 2026 |
Strategic Implications
- Global Development Strategy: Integration of Chinese clinical sites accelerates patient enrollment and supports global regulatory filings
- Prostate Cancer Focus: Addresses significant unmet need in metastatic castration-resistant prostate cancer (mCRPC)
- Target Validation: STEAP1 represents emerging target with strong biological rationale in multiple solid tumor types
- ADC Platform: Demonstrates Adcentrx’s capability to develop novel ADCs against challenging targets
Market Context
- Prostate Cancer Burden: China accounts for approximately 14% of global prostate cancer cases with rising incidence
- ADC Pipeline Competition: Limited STEAP1-targeting agents in clinical development globally
- Chinese Clinical Trials: Increasing importance of Chinese data for global regulatory submissions
- Solid Tumor ADC Market: Rapidly expanding therapeutic area with multiple recent approvals and high commercial value
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory pathways, and strategic objectives. Actual results may differ due to risks including clinical trial outcomes, regulatory decisions, competitive dynamics, and execution challenges in international clinical development.-Fineline Info & Tech